NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

Tags: migraines


Drug’s ability to lower frequency of migraines by 50 percent sounds pretty good–until you read the fine print


Emerging migraine treatments: NPR story deftly weighs the good, the bad and the unknowns


Guardian story on new migraine drug never establishes why it’s ‘an important step forward’


Reuters Health carefully hedges results of study on mild shocks for migraines


Heavy on anecdote and light on evidence: NBC News’s story on experimental migraine drug